Citation

BibTex format

@article{Molyneaux:2022:10.1164/rccm.202107-1769OC,
author = {Molyneaux, PL and Fahy, WA and Byrne, AJ and Braybrooke, R and Saunders, P and Toshner, R and Albers, G and Chua, F and Renzoni, EA and Wells, AU and Karkera, Y and Oballa, E and Saini, G and Nicholson, AG and Jenkins, G and Maher, TM},
doi = {10.1164/rccm.202107-1769OC},
journal = {American Journal of Respiratory and Critical Care Medicine},
pages = {1440--1448},
title = {CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort},
url = {http://dx.doi.org/10.1164/rccm.202107-1769OC},
volume = {205},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal condition for which there are a lack of effective biomarkers to guide therapeutic decision making. RATIONALE: To determine the relationship between serum levels of the cytokeratin fragment CYFRA 21-1 and disease progression and mortality in individuals with IPF enrolled in the PROFILE study. METHODS: CYFRA 21-1 was identified by immunohistochemistry in samples of human lung. Concentrations of CYFRA 21-1 were measured using an Elisa-based assay in serum, collected at baseline, 1- and 3-months, from 491 individuals with an incident diagnosis of IPF enrolled in the PROFILE study and from 100 control subjects. Study subjects were followed for a minimum of 3 years. MEASUREMENTS AND MAIN RESULTS: CYFRA 21-1 localises to hyperplastic epithelium in IPF lung. CYFRA 21-1 levels were significantly higher in IPF subjects compared to healthy controls in both discovery (n=132) (control 0.96±0.81 ng/mL versus IPF; 2.34±2.15 ng/mL, p < 0.0001) and validation (n=359) (control; 2.21±1.54 ng/mL and IPF; 4.13±2.77 ng/mL, p<0.0001) cohorts. Baseline levels of CYFRA 21-1 distinguished individuals at risk of 12-month disease progression (C-statistic 0.70 (95% CI 0.61-0.79), p < 0.0001) and were predictive of overall-mortality (HR 1.12 (1.06-1.19) per 1 ng/mL increase in CYFRA 21-1, p=0.0001). Furthermore, 3-month change in levels of CYFRA 21-1 separately predicted 12-month and overall survival in both the discovery and validation cohorts. CONCLUSIONS: CYFRA 21-1, a marker of epithelial damage and turnover, has the potential to be an important prognostic and therapeutic biomarker in individuals with IPF.
AU - Molyneaux,PL
AU - Fahy,WA
AU - Byrne,AJ
AU - Braybrooke,R
AU - Saunders,P
AU - Toshner,R
AU - Albers,G
AU - Chua,F
AU - Renzoni,EA
AU - Wells,AU
AU - Karkera,Y
AU - Oballa,E
AU - Saini,G
AU - Nicholson,AG
AU - Jenkins,G
AU - Maher,TM
DO - 10.1164/rccm.202107-1769OC
EP - 1448
PY - 2022///
SN - 1073-449X
SP - 1440
TI - CYFRA 21-1 predicts progression in IPF: a prospective longitudinal analysis of the PROFILE cohort
T2 - American Journal of Respiratory and Critical Care Medicine
UR - http://dx.doi.org/10.1164/rccm.202107-1769OC
UR - https://www.ncbi.nlm.nih.gov/pubmed/35363592
UR - https://www.atsjournals.org/doi/10.1164/rccm.202107-1769OC
UR - http://hdl.handle.net/10044/1/96287
VL - 205
ER -

Publications policy

All members of the Centre should be aware of and follow our MTW Research Publication Policy (PDF).

General enquiries


For any enquiries about the Margaret Turner Warwick Centre for Fibrosing Lung Disease, please contact:

admin.mtwc@imperial.ac.uk